Ryght
Founded 2023 · 25 employees on LinkedIn · 7 known investors
Ryght AI provides an artificial intelligence-powered platform that uses digital twin technology to help clinical research organizations and sponsors identify and select optimal sites for clinical trials. The platform analyzes thousands of global research sites to compress traditional site selection timelines from months to weeks while reducing costs and improving enrollment outcomes.
Also known as Ryght AI · Ryght AI, Inc. · Synthetica Bio
Founders & leadership
Investors · 7
Company profile
researched Aug 2026Ryght AI, Inc. (Ryght) develops a generative- and agentic-AI platform for the clinical research industry, focused on automating clinical trial site identification, selection, feasibility, activation and patient enrollment. Its core asset is a network of "AI Site Twins" — digital-twin profiles of clinical research sites that capture operational characteristics, historical trial performance and patient populations, and which the company states covers more than 100,000 sites worldwide. The twins are maintained by AI retriever agents that update them with data from public and other sources, and are used to analyze a trial protocol and return a protocol-matched, performance-ranked list of candidate sites.
Products include RyghtSites.com, a free search engine over 60,000+ global research sites queryable by indication, phase and region; Network Navigator, which ranks and tailors site lists to a specific protocol; and Feasibility Accelerator, which sends AI-generated feasibility questionnaires to qualified sites and tracks responses. Additional capabilities described by the company cover patient pre-screening at sites, protocol adherence management, AI-assisted site budget generation and negotiation from a schedule of events, and medical writing assistants for informed consent forms, protocols and CRO proposals. The platform is SOC 2 compliant and is listed on the Microsoft Azure Marketplace so buyers can transact against existing cloud commitments. Earlier platform materials also describe a life-sciences GenAI environment with enterprise data connectors (Snowflake, Databricks, Confluence, Slack, Google Docs, Adobe PDF, Microsoft SharePoint and Office), custom copilots, natural-language querying of data silos, automatic SQL generation, open-source model fine-tuning, API deployment endpoints and daily LLM performance and cost reporting.
Founding story
Ryght was co-founded by Simon Arkell (Co-Founder & CEO), a technology entrepreneur and investor who co-founded seven venture-backed companies including Deep Lens, Predixion Software and Versifi — which together raised over $100 million and were all acquired — and Alex Dickinson (Co-Founder & Chairman), previously co-founder/chair/CEO of ChromaCode, Helixis (acquired by Illumina) and Luxtera (acquired by Cisco), a seven-year Illumina SVP, and a former board member of PRA Health Sciences and Gencove. Sources give the founding year variously as 2023 and 2024.
Business model
Ryght sells software to trial sponsors, CROs and research sites under what the company terms a "service as software" model, replacing labor-intensive site selection and feasibility services with an AI platform. A free site search engine (RyghtSites.com) and free protocol-based site-list trials serve as top-of-funnel entry points, while the paid platform is also transactable through the Microsoft Azure Marketplace.
Software platform sold to sponsors, CROs and research sites, including purchase through the Microsoft Azure Marketplace against existing cloud commitments; a free site search engine and free protocol evaluations are offered without charge.
Traction
By June 2025 the company reported signing eight academic medical centers since November, including Emory University, West Virginia University and West Clinic, alongside previously announced partners USC Keck School of Medicine and the Medical College of Wisconsin. A published case study describes a global CRO that needed 13 qualified sites for a first-in-human oncology trial and compressed roughly six months of site selection into 26 days, securing more than three times its target. Testimonials come from USC Keck School of Medicine, CRO QPS and the University of Adelaide's Institute for Photonics and Advanced Sensing.
Latest developments
In June 2025 Ryght announced a $3 million seed round led by Foothill Ventures together with new academic medical center partnerships, saying proceeds would accelerate AMC partnerships and expand its platform for trial site identification, selection and activation. Current company materials advertise a protocol-matched site list within 48 hours, availability on the Microsoft Azure Marketplace, and a CRO case study on compressed site selection timelines. Advisors include Tarek Sherif, co-founder and former CEO of Medidata Solutions, and Tom Pike, President and CEO of Labcorp's Clinical Development business.
▸Full profile — market position, technology, go-to-market, geography, history, risks & controversies
Market position
Ryght positions itself against incumbent practice of buying spreadsheets of site data from multiple vendors and manually screening investigators, and targets what it describes as a $140 billion global clinical trial services market in which 55% of trials are said to fail due to poor site feasibility, slow activation and mismatch between site capability and trial needs. It claims the industry's first "AI Site Twins."
A claimed complete, continuously updated digital-twin replica of every clinical research site globally (100,000+ profiles), combined with end-to-end agentic workflows spanning site matching, automated feasibility outreach, budgeting and activation rather than point data licensing.
Technology
Generative and agentic AI applied to clinical trial operations: large language models, machine learning on heterogeneous site datasets, and AI retriever agents that continuously refresh digital-twin site profiles. The platform supports protocol ingestion and analysis, simulation and forecasting of enrollment performance, synthetic testing of protocol changes across the site network, and API-based integration; earlier documentation cites model research, fine-tuning of open-source LLMs, vectorization, prompt engineering and enterprise data connectors. The company states SOC 2 compliance.
Go-to-market
Direct enterprise sales and business development to sponsors and CROs (led by a business development function staffed from the CRO industry), partnerships with academic medical centers, free trial offers in which prospects submit an old protocol for a site list, a free public site-search tool, and cloud-marketplace distribution via Microsoft Azure.
Biopharma and biotech trial sponsors, contract research organizations, and clinical research sites, including academic medical centers.
Geography
Headquartered in Laguna Beach, California, with a corporate address also listed in Anaheim, California; the site-twin network and search coverage are described as global, and partnerships span US academic medical centers plus stated engagement with the University of Adelaide in Australia.
History
The company was previously known as Synthetica Bio before operating as Ryght AI. It signed its first academic medical center partnerships from November (per a June 2025 announcement), added Emory University, West Virginia University, West Clinic and three others by mid-2025, and announced a $3 million seed round in June 2025 that took total capital raised to more than $9 million since inception.
Risks & controversies
Claims such as complete digital-twin coverage of every clinical research site and specific timeline compressions originate from company materials and are not independently verified in the available sources. Site-count figures are inconsistent across materials (60,000+ searchable sites on RyghtSites.com versus 100,000+ digital twins), and reported founding year differs between sources (2023 versus 2024).
Compiled by commissioned research from 8 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Founder mafia
2 people who came through Ryght went on to found or lead other companies.
Timeline · 4
launches, deals, and filingsRyght AI announced a $3 million seed round led by Foothill Ventures with existing investors AIX Ventures, Virtue Ventures, IASO Ventures, Top Harvest Capital and Page One Ventures participating; the company said the round took total raised to over $9 million and would fund academic medical center partnerships and expansion of its site identification, selection and activation platform.
$3M source ↗
Ryght announced new academic medical center partnerships including Emory University, West Virginia University, West Clinic and three others, joining previously announced partners USC Keck School of Medicine and the Medical College of Wisconsin — eight AMCs signed since November.
Ryght is listed on the Microsoft Azure Marketplace, allowing sponsors and CROs to purchase using existing cloud commitments and consolidated billing.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
In the news
▸Research sources · 8
primary sources listed
- Ryghtryght.ai · web
8 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Ryght do?
- Ryght AI runs an agentic AI platform that uses digital twins of clinical research sites to automate trial site selection and feasibility.
- Who are Ryght's investors?
- Ryght's investors include AIX Ventures, Foothill Ventures, Iaso Ventures, Page One Ventures, Virtue Ventures, LDV Partners, Top Harvest Capital.